Dihydroorotate dehydrogenase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as acute myeloid leukemia, RA, multiple sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID19 treatment using DHODH inhibitors.
Report Highlights
This segment of the Dihydroorotate Dehydrogenase (DHODH) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs
Further product details are provided in the report……..
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs.
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as acute myeloid leukemia, RA, multiple sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID19 treatment using DHODH inhibitors.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dihydroorotate Dehydrogenase (DHODH) Inhibitor R&D. The therapies under development are focused on novel approaches for Dihydroorotate Dehydrogenase (DHODH) Inhibitor.
This segment of the Dihydroorotate Dehydrogenase (DHODH) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs
- IMU-838: Immunic
- PTC 299: PTC Therapeutics
Further product details are provided in the report……..
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Dihydroorotate Dehydrogenase (DHODH) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs.
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Insights
- Dihydroorotate Dehydrogenase (DHODH) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs?
- How many Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Dihydroorotate Dehydrogenase (DHODH) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dihydroorotate Dehydrogenase (DHODH) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sanofi
- Immunic
- PTC Therapeutics
- Clear Creek Bio
- EyeGate Pharma
- ASLAN Pharmaceuticals
- Medicines for Malaria Venture
- Teriflunomide
- IMU-838
- Emvododstat
- Olorofim
- Brequinar
- PP 001 EyeGate Pharma
- ASLAN-003
- MMV-1793609
Introduction
Executive Summary
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
Dihydroorotate Dehydrogenase (DHODH) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Dihydroorotate Dehydrogenase (DHODH) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
• Comparative Analysis
IMU-838: Immunic
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
• Comparative Analysis
PP 001: EyeGate Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
MMV-1793609: Medicines for Malaria Venture
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Products
Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet Needs
Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and Barriers
Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and Conclusion
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst Views
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
Appendix
Executive Summary
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
Dihydroorotate Dehydrogenase (DHODH) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Dihydroorotate Dehydrogenase (DHODH) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
• Comparative Analysis
IMU-838: Immunic
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
• Comparative Analysis
PP 001: EyeGate Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
MMV-1793609: Medicines for Malaria Venture
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Products
Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet Needs
Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and Barriers
Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and Conclusion
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst Views
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1Total Products for Dihydroorotate dehydrogenase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1Total Products for Dihydroorotate dehydrogenase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Dihydroorotate dehydrogenase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Dihydroorotate dehydrogenase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
